Galecto

Galecto Debt/EBITDA

Total Debt to EBITDA Ratio of Galecto (GLTO) as of Oct 19, 2026.

Debt/EBITDA

-0.00

YoY

-90.17%

Last updated:

Total Debt to EBITDA Ratio of Galecto is 2025 -0.00 . Total Debt to EBITDA Ratio of Galecto was 2024 -0.00 . It decreases by -90.17% higher compared to the previous year.

The Galecto Debt/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt/EBITDA
Date
Debt/EBITDA
Jan 1, 2019
-0.01 USD
Jan 1, 2020
-0.03 USD
Jan 1, 2021
-0.02 USD
Jan 1, 2022
-0.01 USD
Jan 1, 2023
-0.01 USD
Jan 1, 2024
-0.00 USD
Jan 1, 2025
-0.00 USD
The Galecto Debt/EBITDA history
YEARDebt/EBITDAYoY
-0.00-90.17%
-0.00-47.44%
-0.01-52.50%
-0.01-19.00%
-0.02-40.38%
-0.03+255.74%
-0.01—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Galecto Stock analysis

What does Galecto do? Galecto Inc., based in Boston, US, is a clinical-stage biotechnology company focused on developing small molecule therapeutics targeting cancer and fibrotic diseases. The company, listed on 29 October 2020, employs 7 full-time staff and is advancing several drug candidates, including GB0139 for idiopathic pulmonary fibrosis, GB1211 for oncology and liver cirrhosis, and GB2064 for myelofibrosis. Galecto is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Galecto stock

On Eulerpool you can find the complete historical development of Total Debt to EBITDA Ratio Galecto since 2006 – with annual values, charts, and detailed analysis.

Debt/EBITDA measures total debt relative to earnings before interest, taxes, depreciation, and amortization. It indicates the years needed to repay all debt from EBITDA.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Total Debt to EBITDA Ratio's Galecto with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Galecto

All Key Metrics — Galecto